M&A has been driving a recovery for biotech, with $62 billion in takeouts in the past six months restocking specialist investors’ coffers for their next wave of investments. On the latest BioCentury This Week podcast, BioCentury’s editors assess the state of the public markets heading into the second quarter, including the outsize role PIPEs have had in financing industry’s comeback. They also discuss their takeaways from analyzing nearly 7,000 abstracts from the American Association for Cancer Research and the editors’ insights on why degrader-antibody conjugates are emerging as the next contenders to build on the success of the antibody-drug conjugates paradigm. Editor in Chief Simone Fishburn also previews Grand Rounds, BioCentury’s first R&D conference, which will focus on the biotech industry’s interface with academia, bringing together decision-makers and the next innovators in Nashville Sept. 9-11. To learn more about BioCentury Grand Rounds and opportunities to present, see the conferencewebsite. This week’s podcast is sponsored by Jeito Capital. View full story: https://www.biocentury.com/article/6519960:01 - Sponsor Message: Jeito Capital1:15 - Introducing BioCentury's Grand Rounds3:53 - 2Q Markets Preview12:48 - AACR Takeaways15:46 - ADCs & DACs
Podden och tillhörande omslagsbild på den här sidan tillhör BioCentury. Innehållet i podden är skapat av BioCentury och inte av, eller tillsammans med, Poddtoppen.
